Literature DB >> 22513165

Changes in stigma and discrimination of onchocerciasis in Africa.

Yolande Flore Longang Tchounkeu1, Nkechi G Onyeneho, Samuel Wanji, Asaph Turinde Kabali, Célé Manianga, Uche V Amazigo, Mary Amuyunzu-Nyamongo.   

Abstract

Forms of onchocerciasis-related stigmatisation, following over 10 years of implementation of community directed treatment with ivermectin (CDTI), were documented through a survey conducted between September and November 2009 to look at perceived changes in stigma over the past 7-10 years. We documented people's perceptions towards stigma before and after the introduction of CDTI from 1600 structured interviews with households selected from the community treatment registers; in-depth interviews with 57 community leaders, community directed distributors and health personnel; 33 focus group discussions with male and female community members in different age groups (18-24, 25-54 and ≥55 years) and 13 case studies. People with onchocercal skin disease (OSD) with rough skin, swellings and rashes were the most stigmatised. People still fear sexual intimacy with infected persons. In the past, people with OSD were considered unclean and stigmatised because of fear of OSD transmission and embarrassment. People who had lived in the community less than 5 years tended to stigmatise OSD patients more than those people who had lived in the community for longer than 5 years. The youth stigmatised the most. Although stigmatisation persists, avoidance of people with OSD decreased from 32.7% to 4.3%. It is notable that treatment availability has improved relationships between healthy people and those with OSD symptoms in endemic communities and this can be attributed to CDTI. Health education should be emphasised in the communities during distribution.
Copyright © 2012 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22513165     DOI: 10.1016/j.trstmh.2012.02.009

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  10 in total

1.  Investing in justice: ethics, evidence, and the eradication investment cases for lymphatic filariasis and onchocerciasis.

Authors:  Theodore C Bailey; Maria W Merritt; Fabrizio Tediosi
Journal:  Am J Public Health       Date:  2015-02-25       Impact factor: 9.308

2.  [Knowledge, attitudes and practices of the population of SAMBWA health area in relation to the treatment of onchocerciasis with ivermectin under community directives].

Authors:  Cilundika Mulenga Philippe; Yogolelo Asani Bienvenu; Malonga Kaj Francoise; Mukomena Sompwe Eric; Mukalay Wa Mukalay Abdon; Oscar Numbi Luboya
Journal:  Pan Afr Med J       Date:  2014-12-08

3.  Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment.

Authors:  Guy-Roger Kamga; Fanny N Dissak-Delon; Hugues C Nana-Djeunga; Benjamin D Biholong; Stephen Mbigha-Ghogomu; Jacob Souopgui; Honorat G M Zoure; Michel Boussinesq; Joseph Kamgno; Annie Robert
Journal:  Parasit Vectors       Date:  2016-11-14       Impact factor: 3.876

4.  Community Participation in and Perception of Community-Directed Treatment with Ivermectin in Kinshasa, DRC.

Authors:  Jean-Claude Makenga Bof; Paul Mansiangi; Horlyne Nsangi; Éric Mafuta; Isabelle Aujoulat; Yves Coppieters
Journal:  Trop Med Infect Dis       Date:  2019-07-19

5.  Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo.

Authors:  Jean-Claude Makenga Bof; Daniel Muteba; Paul Mansiangi; Félicien Ilunga-Ilunga; Yves Coppieters
Journal:  BMC Pharmacol Toxicol       Date:  2019-08-16       Impact factor: 2.483

Review 6.  Stigma and epilepsy in onchocerciasis-endemic regions in Africa: a review and recommendations from the onchocerciasis-associated epilepsy working group.

Authors:  Sarah O'Neill; Julia Irani; Joseph Nelson Siewe Fodjo; Denis Nono; Catherine Abbo; Yasuaki Sato; Augustine Mugarura; Housseini Dolo; Maya Ronse; Alfred K Njamnshi; Robert Colebunders
Journal:  Infect Dis Poverty       Date:  2019-05-20       Impact factor: 4.520

7.  Socioeconomic impacts of elimination of onchocerciasis in Abu-Hamed focus, northern Sudan: lessons after elimination.

Authors:  Ayman Ahmed; Anas Elbashir; Asgad A Mohamed; Asha A Alim; Asia Mubarak; Duaa Abdelrahman; Eilaf Mohammed; Nouh S Mohamed; Arwa H Elaagip; Isam M A Zarroug; Noma Mounkaila; Hanan Tahir
Journal:  BMC Res Notes       Date:  2020-05-26

8.  Health-related quality of life and associated factors among Onchocerciasis patients in southeast Nigeria: A cross-sectional comparative study.

Authors:  Adah E Otache; Ifeyinwa L Ezenwosu; Edmund N Ossai; Elias C Aniwada; Emmanuel A Nwobi; Benjamin Sc Uzochukwu
Journal:  PLoS Negl Trop Dis       Date:  2022-02-09

Review 9.  Optimizing G6PD testing for Plasmodium vivax case management and beyond: why sex, counseling, and community engagement matter.

Authors:  Cindy S Chu; Germana Bancone; Maureen Kelley; Nicole Advani; Gonzalo J Domingo; Eva M Cutiongo-de la Paz; Nicole van der Merwe; Jessica Cohen; Emily Gerth-Guyette
Journal:  Wellcome Open Res       Date:  2020-08-25

Review 10.  Onchodermatitis: Where Are We Now?

Authors:  Michele E Murdoch
Journal:  Trop Med Infect Dis       Date:  2018-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.